SG11202011311YA - Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway - Google Patents
Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathwayInfo
- Publication number
- SG11202011311YA SG11202011311YA SG11202011311YA SG11202011311YA SG11202011311YA SG 11202011311Y A SG11202011311Y A SG 11202011311YA SG 11202011311Y A SG11202011311Y A SG 11202011311YA SG 11202011311Y A SG11202011311Y A SG 11202011311YA SG 11202011311Y A SG11202011311Y A SG 11202011311YA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- heat shock
- diseases associated
- shock protein
- modified sugar
- Prior art date
Links
- -1 Biaryl amides Chemical class 0.000 title 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 title 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671047P | 2018-05-14 | 2018-05-14 | |
| PCT/US2019/032292 WO2019222269A1 (en) | 2018-05-14 | 2019-05-14 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202011311YA true SG11202011311YA (en) | 2020-12-30 |
Family
ID=67002352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202011311YA SG11202011311YA (en) | 2018-05-14 | 2019-05-14 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11827664B2 (en) |
| EP (1) | EP3794009A1 (en) |
| JP (1) | JP2021524439A (en) |
| KR (1) | KR20210021457A (en) |
| CN (1) | CN112513058A (en) |
| AU (1) | AU2019271126A1 (en) |
| BR (1) | BR112020023277A2 (en) |
| CA (1) | CA3100333A1 (en) |
| CL (1) | CL2020002957A1 (en) |
| CO (1) | CO2020015380A2 (en) |
| EA (1) | EA202092727A1 (en) |
| IL (2) | IL278698B1 (en) |
| MX (1) | MX2020012366A (en) |
| PE (1) | PE20211917A1 (en) |
| PH (1) | PH12020551941A1 (en) |
| SG (1) | SG11202011311YA (en) |
| WO (1) | WO2019222269A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3793565B1 (en) | 2018-05-14 | 2022-01-05 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| TWI778443B (en) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1 inhibitors |
| CN114787139A (en) | 2019-11-26 | 2022-07-22 | 吉利德科学公司 | Processes and intermediates for preparing MCL1 inhibitors |
| US20230138729A1 (en) * | 2021-09-13 | 2023-05-04 | Rubedo Life Sciences, Inc. | Coumarin Derivatives of Sugar Analogs and Uses Thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8612491A (en) | 1990-09-07 | 1992-03-30 | Schering Corporation | Antiviral compounds |
| FR2792320B1 (en) | 1999-04-19 | 2003-05-09 | Hoechst Marion Roussel Inc | NOVEL AROMATIC AMIDES SUBSTITUTED BY RIBOSIS, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
| AU2002223127A1 (en) | 2000-11-30 | 2002-06-11 | Kissei Pharmaceutical Co., Ltd. Intellectual Property | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| US7208630B2 (en) | 2004-10-27 | 2007-04-24 | University Of Kansas | Heat shock protein 90 inhibitors |
| US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| US7608594B2 (en) | 2004-11-03 | 2009-10-27 | University Of Kansas | Novobiocin analogues as anticancer agents |
| US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US8212011B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues |
| US8212012B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| ATE484499T1 (en) | 2005-08-30 | 2010-10-15 | Boehringer Ingelheim Int | GLUCOPYRANOSYL-SUBSTITUTED BENZYL DERIVATIVES, MEDICATIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PRODUCTION METHOD THEREOF |
| US8044041B2 (en) | 2006-11-15 | 2011-10-25 | Forest Laboratories Holdings Limited | Phthalazine derivatives as inhibitors of protein kinase |
| DE102007002715A1 (en) * | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | triazole |
| RS52978B (en) | 2007-03-20 | 2014-02-28 | Curis, Inc. | Fused amino pyridine as hsp90 inhibitors |
| US7960353B2 (en) | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| WO2010014617A1 (en) | 2008-07-28 | 2010-02-04 | University Of Kansas | Heat shock protein 90 inhibitor dosing methods |
| JP5766617B2 (en) | 2009-02-20 | 2015-08-19 | ユニバーシティ・オブ・カンザス | Novobiocin analogs having modified sugar moieties |
| WO2011041593A1 (en) | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
| JPWO2012008435A1 (en) | 2010-07-13 | 2013-09-09 | 大日本住友製薬株式会社 | Biarylamide derivatives or pharmacologically acceptable salts thereof |
| AU2012240079B2 (en) | 2011-04-05 | 2017-05-18 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| US9056104B2 (en) | 2011-05-20 | 2015-06-16 | The University Of Kansas | Dynamic inhibitors of heat shock protein 90 |
| DK2812341T3 (en) | 2012-02-09 | 2019-11-18 | Univ Kansas | C-TERMINAL HSP90 INHIBITORS |
| US9422230B2 (en) | 2013-05-09 | 2016-08-23 | Council Of Scientific And Industrial Research | Process for the preparation of an anticonvulsant agent pregabalin hydrochloride |
| CA2928951C (en) | 2013-11-07 | 2023-10-17 | The University Of Kansas | Biphenylamide derivative hsp90 inhibitors |
| AU2014346368B2 (en) | 2013-11-11 | 2019-03-14 | The University Of Kansas | Coumarin based Hsp90 inhibitors with urea and ether substituents |
| WO2015192099A1 (en) | 2014-06-13 | 2015-12-17 | The University Of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
| NZ728482A (en) * | 2014-06-24 | 2022-11-25 | Univ Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
-
2019
- 2019-05-14 AU AU2019271126A patent/AU2019271126A1/en active Pending
- 2019-05-14 SG SG11202011311YA patent/SG11202011311YA/en unknown
- 2019-05-14 MX MX2020012366A patent/MX2020012366A/en unknown
- 2019-05-14 US US17/055,331 patent/US11827664B2/en active Active
- 2019-05-14 CA CA3100333A patent/CA3100333A1/en active Pending
- 2019-05-14 IL IL278698A patent/IL278698B1/en unknown
- 2019-05-14 JP JP2020564427A patent/JP2021524439A/en active Pending
- 2019-05-14 EP EP19732770.3A patent/EP3794009A1/en active Pending
- 2019-05-14 WO PCT/US2019/032292 patent/WO2019222269A1/en unknown
- 2019-05-14 PE PE2020001859A patent/PE20211917A1/en unknown
- 2019-05-14 CN CN201980046311.2A patent/CN112513058A/en active Pending
- 2019-05-14 IL IL309891A patent/IL309891A/en unknown
- 2019-05-14 BR BR112020023277-7A patent/BR112020023277A2/en unknown
- 2019-05-14 EA EA202092727A patent/EA202092727A1/en unknown
- 2019-05-14 KR KR1020207033977A patent/KR20210021457A/en active Search and Examination
-
2020
- 2020-11-13 CL CL2020002957A patent/CL2020002957A1/en unknown
- 2020-11-13 PH PH12020551941A patent/PH12020551941A1/en unknown
- 2020-12-09 CO CONC2020/0015380A patent/CO2020015380A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021524439A (en) | 2021-09-13 |
| EP3794009A1 (en) | 2021-03-24 |
| MX2020012366A (en) | 2021-02-09 |
| CA3100333A1 (en) | 2019-11-21 |
| CO2020015380A2 (en) | 2020-12-21 |
| BR112020023277A2 (en) | 2021-02-23 |
| KR20210021457A (en) | 2021-02-26 |
| IL309891A (en) | 2024-03-01 |
| EA202092727A1 (en) | 2021-04-20 |
| IL278698B1 (en) | 2024-02-01 |
| CL2020002957A1 (en) | 2021-04-16 |
| IL278698A (en) | 2021-01-31 |
| PE20211917A1 (en) | 2021-09-28 |
| AU2019271126A1 (en) | 2020-12-10 |
| US11827664B2 (en) | 2023-11-28 |
| PH12020551941A1 (en) | 2021-08-16 |
| CN112513058A (en) | 2021-03-16 |
| WO2019222269A1 (en) | 2019-11-21 |
| US20210261592A1 (en) | 2021-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202011311YA (en) | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | |
| IL251326A0 (en) | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 | |
| DK3673080T3 (en) | ANTISENSE OLIGOMERS FOR THE TREATMENT OF DISORDERS AND DISEASES | |
| HK1246712A1 (en) | Nerve stimulation for treatment of diseases and disorders | |
| IL287823A (en) | Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders | |
| ZA201702214B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| EP3148569A4 (en) | Therapeutic tratment of skin disease with recombinant commensal skin microorganisms | |
| IL270746A (en) | Heat shock protein inducers and frontotemporal disorders | |
| ZA202101587B (en) | Protein for treatment of inflammatory diseases | |
| ZA202000595B (en) | Novel therapeutic enzyme fusion protein and use thereof | |
| PL3500586T3 (en) | Continuous process for reducing heterogeneity of therapeutic protein | |
| IL270781A (en) | Treatment of depressive disorders | |
| IL283901A (en) | Pharmaceutical process and intermediates | |
| EP3258930A4 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | |
| SG11201705677WA (en) | Pulsating electromagnetic and ultrasound therapy for stimulating targeted heat shock proteins and facilitating protein repair | |
| EP3341012A4 (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| IL249485A0 (en) | O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated an accumulation of misfolded proteins | |
| HK1245671A1 (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| FR3044227B1 (en) | AMINOPHOSPHINE DERIVATIVES FOR THE PREVENTION AND TREATMENT OF EYE PAIN | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| EP3420111C0 (en) | Process for targeted heat treatment of individual component zones | |
| IL284411A (en) | Targeted delivery of therapeutic molecules | |
| EP3615561C0 (en) | Variants of human bmp7 protein | |
| HK1256714A1 (en) | Methods of manufacturing therapeutic proteins | |
| IL259381B (en) | Mirabegron for the treatment of retinal diseases |